Products
Sofituzumab Vedotin Biosimilar Antibody-Drug Conjugate (MUC16) for Research
Pre-made Sofituzumab Vedotin benchmark antibody (Whole mAb ADC, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sofituzumab vedotin (INN;[1] development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer.[2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-994-1mg | 1mg | 4635 |
| GMP-Bios-INN-994-10mg | 10mg | |
| GMP-Bios-INN-994-100mg | 100mg | |
| GMP-Bios-INN-994-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sofituzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Muc16 Antibody: Anti-CA125 therapeutic antibody Drug Conjugate |
| INN Name | Sofituzumab Vedotin |
| Target | MUC16 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - MUC16
1. Protein Mucin-16
2. Gene MUC16
3. Organism Homo sapiens (Human)
Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Miscellaneous
Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.
